
The complement system is a key part of the innate immune system and plays an important role in the clearance of pathogens and apoptotic cells upon its activation. It is well known that both IgG and IgM can activate complement via the classical pathway by binding of C1q to the Fc regions of these immunoglobulins. Recent advances have shown that also IgA is capable of activating the complement system. Besides, more insight is gained into an additional role for antibodies in the activation of both the alternative and the lectin pathways. Mouse models have shown that auto-antibodies can activate the alternative pathway and induce in cell lysis and tissue damage. Besides the role of antibodies in complement activation, complement may also be a target for recognition by antibodies directed against autologous complement components. These auto-antibodies play a role in several diseases, especially vascular diseases. Understanding how antibodies interact with the complement system will allow the manipulation of this interaction to diminish pathological consequences of auto-antibodies and optimize the effect of therapeutic antibodies. In the current review, we discuss complement activation by (auto-) antibodies by the different pathways.
Antibodies, Monoclonal, Epidermolysis Bullosa Acquisita, Arthritis, Experimental, Immunoglobulin A, Disease Models, Animal, Mice, Immunoglobulin M, Immunoglobulin G, Pemphigoid, Bullous, Complement Antibody Autoimmunity Therapy systemic-lupus-erythematosus epidermolysis-bullosa-acquisita chronic lymphocytic-leukemia mannose-binding lectin cyclic citrullinated peptide hemolytic-uremic syndrome anti-cd20 monoclonal-antibodies pathway c-3 convertase non-hodgkin lymphomas fresh-frozen plasma, Animals, Humans, Lupus Erythematosus, Systemic, Complement Activation, Autoantibodies
Antibodies, Monoclonal, Epidermolysis Bullosa Acquisita, Arthritis, Experimental, Immunoglobulin A, Disease Models, Animal, Mice, Immunoglobulin M, Immunoglobulin G, Pemphigoid, Bullous, Complement Antibody Autoimmunity Therapy systemic-lupus-erythematosus epidermolysis-bullosa-acquisita chronic lymphocytic-leukemia mannose-binding lectin cyclic citrullinated peptide hemolytic-uremic syndrome anti-cd20 monoclonal-antibodies pathway c-3 convertase non-hodgkin lymphomas fresh-frozen plasma, Animals, Humans, Lupus Erythematosus, Systemic, Complement Activation, Autoantibodies
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 138 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 1% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 1% |
